Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Anthera Pharmaceuticals, Inc.
Shares of the biopharmaceutical company have fallen nearly 90 percent year-to-date. The company recently announced that that an abstract of the results from the Phase 2b PEARL-SC clinical study has been accepted as a late-breaking poster presentation at the ACR/ARHP 2012 Annual Scientific Meeting.
Going forward ... (see research report)
Subscribe to News Feeds